Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Nanjing IASO Bio Raises $60 Million in B Round for Cell Therapies

publication date: Mar 23, 2020

Nanjing IASO Biotherapeutics completed a $60 million Series B financing led by GL Ventures, a Hillhouse Capital VC focusing on early-stage innovative companies. Founded in 2017, IASO is developing cell therapies for oncology conditions, with more than 10 pipeline products led by autologous and universal CAR-T products for hematological tumors. It is also working on novel TCR-like CAR-T cell therapies for solid tumor indications. Last year, IASO and Innovent announced their anti-BCMA CAR-T produced a 100% overall response rate in patients with relapsed/refractory multiple myeloma. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
August 25-27, 2020
China Standard Time
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China